Hutchison China Meditech Ltd - Hong Kong-based pharmaceutical company - Says it has initiated two international phase I studies of oncology drug candidate HMPL-306. One trial is in patients with advanced solid tumors and the other trial is in patients with hematological malignancies. Both trials have sites in the US and Europe. The first international patient was dosed last Thursday, following a phase I trial that was initiated in China in the second half of 2020.
Current stock price: 392.00 pence
Year-to-date change: down 15%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)